This July, the PrEvCan campaign is dedicated to raising awareness about women’s cancer risk in connection with breastfeeding and hormone replacement therapy (HRT).
Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of cancer.
In support of this initiative, and to help improve the dialogue between patients and healthcare professionals, we had the pleasure of engaging in conversation with advanced oncology nurse practitioner, Celia Diez de los Rios (EONS Education Working Group Co-Chair). In this interview we discussed current knowledge regarding the link between HRT and the development of specific cancers. We also explored the available evidence relating to the impact of HRT on cancer risk, including the effects of different durations, formulations, and treatment regimens. Additionally, we discussed particular populations that may be more susceptible to the potential influence of HRT on cancer risk.
- What is the current evidence supporting the use of Hormone Replacement Therapy (HRT) for managing menopausal symptoms in women? (0:22)
- Based on recent clinical data, what does the research indicate about the relationship between HRT use and the risk of developing cancer? (1:06)
- Are there differences in cancer risk associated with different formulations and regimens of HRT? (2:01)
- Does the duration of HRT use impact the risk of developing cancer? (3:00)
- Are there specific populations or groups of women who may be more susceptible to the cancer risk associated with HRT? (3:25)
- What advice would you give to women experiencing menopausal symptoms who are considering or currently using HRT? (4:05)
Disclosures: Celia Diez de los Rios has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
To learn more about the campaign, and download toolkits and videos to help you spread the PrEvCan messages visit: https://cancernurse.eu/prevcan/
Share this Video
Related Videos In Policy
Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly
The PrEvCan – Cancer Prevention Across Europe – campaign, initiated by the European Oncology Nursing Society (EONS) and supported by ESMO, aims to reduce the burden of cancer by promoting a different way we can decrease cancer risk each month. This August, the PrEvCan campaign focuses on raising awareness about the connection between human papillomavirus […]
Vivek Subbiah, AACR 2023: The purpose of phase I clinical trials
The purpose of phase I clinical trials are to evaluate the safety, dosage and potential side effects of a new drug or treatment in humans for the first time. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) to discuss the purpose and details […]
Vivek Subbiah, AACR 2023: The evolution of phase I clinical trials in the era of precision medicine
Precision medicine aims to tailor medical treatments to individual patients based on their characteristics and genetic makeup. Phase I clinical trials are seeing changes in their objectives and designs in the era of precision medicine. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!